Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Results of regression models: Regression coefficients of AATD patients with and without AT

From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Regression coefficients  
HRQL   SGRQ CAT EQ-5D-3 L utility EQ-5D VAS
Group A Ref. Ref. Ref. Ref.
B1 2.68 (−0.82 – 6.19) 0.66 (−0.73 – 2.04) −0.55 (−4.45 – 3.35) −1.58 (−5.23 – 2.07)
B2 −0.64 (−7.53 – 6.24) 0.60 (−2.09 – 3.31) −1.67 (−9.34 – 6.00) 2.14 (−5.01 – 9.30)
  1. Group A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), Group B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without augmentation therapy
  2. EQ-5D-3 L utility was multiplied by 100
  3. Significant estimates on a level of p < 0.05 are printed bold